GlassScriptPhysician profile
Ibrahim William Sidhom
NPI 1851301220
$4,510.79
in general payments reported to CMS, 2019-2025
48 companies · $539 in 2025
The $539 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $600 · 2020: $615 · 2021: $836 · 2022: $637 · 2023: $628 · 2024: $655 · 2025: $539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,823.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,822.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $761.80 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $693.45 | 2019-2024 | Ozempic, Rybelsus |
| Corcept Therapeutics | $481.01 | 2020-2025 | Korlym |
| Abbott Laboratories | $303.16 | 2021-2025 | Freestyle Libre |
| Astrazeneca Pharmaceuticals LP | $245.00 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $233.11 | 2022-2025 | Ingrezza, Ongentys |
| Ucb, INC. | $138.21 | 2019-2025 | Briviact, Nayzilam |
| Insulet Corporation | $126.13 | 2023-2025 | Omnipod |
| Sunovion Pharmaceuticals INC. | $113.07 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.31 | 2019-2025 | Jardiance |
| Xeris Pharmaceuticals, INC. | $89.35 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Scilex Pharmaceuticals INC. | $87.33 | 2022-2023 | Ztlido |
| Lundbeck LLC | $84.99 | 2022-2024 | Vyepti |
| Dexcom, INC. | $80.12 | 2023-2024 | Dexcom G6 Transmitter |
| Amneal Pharmaceuticals LLC | $78.46 | 2020-2021 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $74.09 | 2019-2021 | |
| Amarin Pharma, INC. | $73.70 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $51.07 | 2020-2023 | |
| Medtronic Minimed, INC. | $45.90 | 2019-2020 | |
| Embecta Corp. | $44.70 | 2023-2024 | Bd Nano 2nd Gen Pen Needle |
| Abbvie INC. | $40.89 | 2022-2025 | |
| Biogen, INC. | $33.07 | 2019-2020 | |
| Ibsa Pharma INC. | $32.72 | 2024-2025 | Tirosint, Licart, Flector |
| Kyowa Kirin, INC. | $32.06 | 2019-2023 | Crysvita |
| Pfizer INC. | $31.80 | 2021 | |
| Recordati_rare_diseases_inc. | $31.78 | 2024 | Signifor Lar, Isturisa |
| Alexion Pharmaceuticals, INC. | $28.08 | 2020-2021 | |
| Lifescan, INC. | $27.94 | 2019-2020 | |
| Mannkind Corporation | $25.95 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $25.90 | 2019-2020 | |
| Medtronic, INC. | $22.96 | 2021 | |
| Madrigal Pharmaceuticals | $20.23 | 2025 | Rezdiffra |
| Sequel Med Tech, LLC | $19.59 | 2025 | Twiist |
| Ultragenyx Pharmaceutical INC. | $19.00 | 2023 | Crysvita |
| Celgene Corporation | $18.96 | 2025 | Zeposia |
| Genentech USA, INC. | $16.36 | 2019 | |
| Cequr Corporation | $16.11 | 2024 | Cequr Simplicity |
| Supernus Pharmaceuticals, INC. | $15.84 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.79 | 2025 | Austedo Xr |
| Daiichi Sankyo INC. | $15.75 | 2023 | Injectafer |
| Averitas Pharma INC. | $15.51 | 2024 | Qutenza |
| Vertical Pharmaceuticals, LLC | $14.92 | 2019 | |
| Eisai INC. | $14.91 | 2023 | |
| Aquestive Therapeutics, INC. | $14.50 | 2022 | |
| Janssen Pharmaceuticals, INC | $14.39 | 2019 | |
| Sk Life Science, INC. | $14.17 | 2022 | |
| Argenx US, INC. | $14.10 | 2024 | Vyvgart Hytrulo |
| Amgen INC. | $11.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ibrahim Sidhom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.